Financial News · Live Terminal

Page 1 of 531

General Dynamics Unit Wins $1.3 Billion Army National Guard IT, Cybersecurity Contract

General Dynamics (GD) unit GDIT was awarded a $1.3 billion contract to provide enterprise IT and cybersecurity services for the US Army National Guard and other federal government partners, the company said Friday.The Enterprise Network Operations and Cybersecurity Support contract, awarded by the General Services Administration's Assisted Acquisition Services, has a one-year base period and six one-year option periods, the company said.GDIT will operate, modernize, integrate and defend the Guard's classified and unclassified networks, the company said.The company said it will also provide integrated IT services, including establishing new operations centers, workforce support and technology provisioning, while deploying artificial intelligence, data analytics and communication capabilities to enhance mission execution.Price: $389.56, Change: $+2.64, Percent Change: +0.68%

$GD

Wire11m ago

Pulse Biosciences Shares Rise After Q2 Results

Pulse Biosciences (PLSE) shares were up 6.6% in Friday trading, a day after the company reported its Q2 results.The company posted a Q2 net loss of $0.36 per diluted share, widening from a loss of $0.28 a year earlier.Three analysts polled by FactSet expected a $0.36 loss.Revenue for the quarter ended June 30 was $434,000.Three analysts expected $500,000.Pulse Biosciences said cash and cash equivalents totaled $101.6 million as of June 30.Price: $40.76, Change: $+2.52, Percent Change: +6.58%

$PLSE

Wire19m ago

FIGS Shares Rise After Q2 Earnings, Revenue Increase

FIGS (FIGS) shares rose 28% in Friday trading after it reported Q2 earnings late Thursday of $0.15 per diluted share, up from $0.04 a year earlier.Analysts polled by FactSet expected $0.07.Net revenue for the quarter ended June 30 was $196.6 million, up from $152.6 million a year earlier.Analysts polled by FactSet expected $186.2 million.Price: $14.37, Change: $+3.13, Percent Change: +27.85%

$FIGS

Wire29m ago

Tango Therapeutics Executive Chair Barbara Weber Departs

Tango Therapeutics (TNGX) executive chairman Barbara Weber has decided to step down from the role, the company said late Thursday.Weber's employment with the company as its executive chair ended on Aug. 3, the company said in a regulatory filing, adding that the resignation was not a result of any disagreement on any matter relating to the company's operations, practices or policies.Shares were down nearly 6% in Friday afternoon trading.Price: $27.22, Change: $-1.78, Percent Change: -6.14%

$TNGX

Wire32m ago

Tandem Diabetes Care's Underlying Q2 Trends Better Than Headline Suggests, RBC Says

Tandem Diabetes Care (TNDM) delivered a stronger underlying Q2 than the headline results suggested, with improving execution and faster-than-expected adoption of its PayGo subscription model, RBC Capital Markets said.The company's PayGo subscription model is gaining significant traction in its first full quarter, with 10% of US sales coming through pharmacy channels. Formulary coverage has reached 45%, already approaching the high end of Tandem's full-year target, according to the note Thursday.The near-term headwind from zero-upfront PayGo pump shipments was about $8 million in Q2, but was more than offset by favorable supply pricing. RBC called PayGo a "transformational shift" that more than doubles expected lifetime revenue per patient while removing the largest barrier to pump adoption.The investment firm also said underlying US pump demand remains healthy, with record second-quarter shipments of 22,000 pumps, sequential growth of more than 20% in new starts and continued strength in multiple daily injection conversions.Tandem submitted an application for its Mobi Tubeless insulin delivery system, with management targeting clearance and a scaled launch in H2. If launched on schedule, 2027 would be the first full year of contribution from the product, which RBC expects to drive meaningful revenue acceleration and margin expansion.RBC maintained the company's stock rating at outperform and adjusted the price target to $26 from $30.Shares of Tandem Diabetes were up more than 17% in Friday trading.Price: $22.07, Change: $+3.28, Percent Change: +17.46%

$TNDM

Wire32m ago

BlossomHill Therapeutics Shares Fall in Nasdaq Debut

BlossomHill Therapeutics (BLSM) shares fell 2.3% to $15.63 in their Nasdaq debut on Friday.The stock opened at $15.75 and reached $16 before trading as low as $15.25.The company priced its upsized initial public offering of 9.375 million common shares at $16 each, raising $150 million in gross proceeds.The underwriters were granted a 30-day option to buy up to an additional 1.4 million shares.The offering is expected to close Monday.Price: $15.63, Change: $-0.37, Percent Change: -2.31%

$BLSM

Wire34m ago

Datadog's AI Cohort Continues to Grow Rapidly, Oppenheimer Says

Datadog's (DDOG) artificial intelligence cohort continues to grow rapidly and is diversifying, including 750 and more AI-native customers, all 10 of the largest AI companies, with eight spending $10 million and more annually, Oppenheimer said in a Thursday research note.Oppenheimer said that the company's guidance for the full year appears to be fully derisked after its largest customer OpenAI renewed in Q3 with lower usage expected, allowing better clarity on the overall business performance.The brokerage also said that the difference between the company's raised guidance for 2026 and investor expectations reflects the company's measured approach.Oppenheimer maintained the company's outperform rating with a $300 price target.Price: $235.35, Change: $+6.06, Percent Change: +2.64%

$DDOG

Wire38m ago

Latigo Biotherapeutics Shares Rise in Nasdaq Debut

Latigo Biotherapeutics (LTGO) shares rose 2.6% to $18.46 in their Nasdaq debut on Friday.The stock opened at $21 and traded as high as $22.47.The company priced its upsized initial public offering of 19.2 million common shares at $18 each on Thursday, raising $345.6 million in gross proceeds.Underwriters were granted 30-day option to purchase up to 2.9 million additional shares.Price: $18.46, Change: $+0.46, Percent Change: +2.56%

$LTGO

Wire48m ago

Lyft's Growth Outlook Lifted by Partnerships, International Expansion, UBS Says

Lyft's (LYFT) growth should continue to be supported by partnerships, premium offerings, shared bikes and international markets following strong Q2 results, UBS Securities said Friday in a report.UBS raised its estimates after management guided to healthy Q3 growth across rideshare, bikes and Freenow, a European ride-hailing and mobility platform. Gross bookings in Q2 rose 23% from a year earlier, while active riders reached a record 30.5 million, the report said.Progress in Lyft's core US rideshare business remains important to monitor, and adjusted EBITDA margins will need to improve from 3.2% of gross bookings to reach the company's 4% margin target for 2027, the report said.UBS raised its price target on Lyft stock $17 from $16 and maintained its neutral rating.Price: $17.27, Change: $+0.97, Percent Change: +5.92%

$LYFT

Wire48m ago

Atlassian's Fiscal Q4 Data Center Upside Driven by End-of-Life Revenue Recognition, Oppenheimer Says

Atlassian's (TEAM) fiscal Q4 data center upside was primarily driven by upfront end-of-life revenue recognition, while cloud acceleration reflects robust seat expansion amid enterprise adoption and growing usage of its Rovo offerings, Oppenheimer said in a Thursday research report.The robust Q4 results reinforce confidence in the company's ability to monetize client AI usage, with potential to deliver more upside by showcasing the relevance of its Teamwork Graph, according to the note.Analysts noted that gross margin outlook calls for a decline, while execution risk remains for evolving data center migration, but a robust quarter makes a case for why AI is a tailwind for its business.The brokerage said it reiterated its outperform rating on the stock and boosted its price target to $200 per share from $110.Price: $148.15, Change: $+37.98, Percent Change: +34.47%

$TEAM

Wire50m ago

Teleflex's 2027 Framework is Achievable, RBC Capital Markets Says

Teleflex (TFX) shares moved on Interventional headwinds and the related 2026 revenue guidance revision, while the Q2 beat remains encouraging and 2027 framework is achievable, RBC Capital Markets said in a note emailed Friday.The company's Q2 beat reflects strong execution in the Vascular and Surgical segments, both of which grew at an above-market high-single-digit pace in H1, the firm highlighted. Management noted that growth will moderate in H2 as Vascular distributor inventories normalize and Surgical faces harder comps, with Q3 seasonality factored in, according to the note.RBC believes a clear path to durable mid-single-digit growth for Teleflex is important to share performance in the mid-to- long term, which it thinks is achievable.The company called out three factors, including order-to-cash customer confusion, distributor timing gaps, and sales force transitions with open positions taking nearly 6 months to ramp, which RBC sees as short-term headwinds that are solely integration-related and not indicative of weakness in the underlying product portfolio, the note added.RBC sees the 2027 framework as achievable and the current pullback as a buying opportunity given earnings power trajectory.RBC kept an outperform rating on Teleflex with a price target of $155.Price: $134.15, Change: $-4.74, Percent Change: -3.42%

$TFX

Wire1h ago

Xenon Pharmaceuticals' Azetukalner NDA Filing Remains on Track After FDA Meeting, RBC Says

Xenon Pharmaceuticals' (XENE) recent pre-NDA meeting with the FDA for azetukalner appeared constructive, supporting the drug's planned Q3 new drug application filing and potential 2027 launch, RBC Capital Markets said.The investment firm said in a Thursday note that azetukalner, Xenon's investigational treatment for focal onset seizures, remains on track for submission later this quarter. It added that the FDA appeared receptive to including all four doses on the drug's label.RBC said payer engagement has been encouraging, with potential for azetukalner to command a premium to Xcopri pricing given its novel mechanism of action, efficacy profile, lack of titration requirements, minimal drug-drug interactions and favorable tolerability.The investment firm also cited early-stage pain program data showing plasma and cerebrospinal fluid concentrations above predicted therapeutic exposures for Xenon's investigational candidates, though it said the safety profile remains unclear pending completion and full unblinding of the phase 1 studies.RBC lowered its price target on Xenon Pharmaceuticals to $81 from $82 while reiterating its outperform rating.Price: $63.35, Change: $-1.20, Percent Change: -1.86%

$XENE

Wire1h ago

Watts Water Seen Benefiting From Data-Center Boom, Europe Recovery, RBC Says

Watts Water Technologies (WTS) may benefit from rapid data-center expansion, improving demand in Europe and stronger margins, though pricing gains are expected to slow, RBC Capital Markets said Thursday in a report.Data-center sales in Q2 more than tripled from a year earlier and now account for about 8% of year-to-date revenue, with liquid-cooling applications offering particularly strong opportunities as customers use more water and thermal-management equipment, the report said.Europe also showed a meaningful recovery, with organic sales rising 9% after almost two years of declines, and the improvement appears sustainable into H2, RBC said.Watts estimates its data-center market opportunity at about $2 billion and expects that segment to grow 15% to 20% annually through 2030, though the timing of large projects may make future sales uneven, RBC said.RBC lifted its 2026 earnings estimate by $1 a share and expects pricing to decelerate in H2 as earlier tariff-related price increases are compared with higher levels from a year earlier.RBC raised its price target on Watts stock to $417 from $350 and maintained its sector-perform rating.Price: $387.08, Change: $+9.96, Percent Change: +2.64%

$WTS

Wire1h ago

Update: Market Chatter: OpenAI Slows Release of Astra Model Over Cyber Concerns

(Update with OpenAI's statement in the last paragraph.)Microsoft-backed (MSFT) OpenAI is slowing down development of its new Astra model and is scaling up testing because it cannot "rule out critical cyber capabilities," Axios reported Friday, citing the company.The timing of the release is unclear, but the pause in its development could cause any future release to be delayed, the report said."Our latest internal evaluations of Astra, one of our upcoming models, over the past few days indicate significant advancements in agentic coding and cybersecurity," OpenAI said in a post. "These results, in addition to expert assessments, have led us to conclude last night that we cannot rule out critical cyber capabilities under our Preparedness Framework."(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $500.68, Change: $+0.82, Percent Change: +0.16%

$MSFT

Wire1h ago

Top Midday Decliners

The Trade Desk (TTD) stock was down 22% amid heavy trading as multiple analyst downgrades followed the company's downbeat Q2 adjusted earnings and revenue.More than 107.0 million shares of the company traded intraday compared with a daily average of about 18.8 million.PN Smart Energy (PN) said Friday it priced a registered direct offering with an institutional investor for the sale of up to 1.43 million Class A shares and pre-funded warrants to raise gross proceeds of $5 million.Shares sank 60%, with intraday trading volume rising to over 2.22 million from a daily average of roughly 686,000.CVRx (CVRX) shares sank 59% amid heavy trading after the company posted Q2 financial results late Thursday. Piper Sandler downgraded the company to neutral from overweight while adjusting its price target to $4 from $12.Over 10.7 million shares of CVRx traded intraday, versus a daily average of roughly 315,000.Price: $13.82, Change: $-3.86, Percent Change: -21.82%

$CVRX$PN$TTD

Wire1h ago

Cloudflare Poised for Further Upside From Agentic AI Traffic Growth, Oppenheimer Says

Cloudflare (NET) is expected to benefit from the rise in agentic artificial intelligence traffic, as the company is well-positioned for edge computing due to its V8 isolate technology and strong adoption of its newer security products, Oppenheimer said in a note emailed Friday.The brokerage said while the web infrastructure and security company has guided to a slowdown in the second half, the deceleration shows a shift toward pool of funds contracts rather than weakening demand.The outlook appears "conservative" for it does not account for the potential gains from the "unprecedented growth" in agentic AI traffic, the firm added.Oppenheimer reaffirmed its outperform rating and raised its price target to $380 from $330, citing further upside from agentic AI traffic.Price: $303.77, Change: $+19.34, Percent Change: +6.80%

$NET

Wire1h ago

VSE's Q2 Strength Supports Higher Full-Year Outlook, RBC Capital Markets Says

VSE (VSEC) delivered another strong quarter in Q2 as organic growth and margin expansion exceeded expectations, supporting a higher full-year outlook, RBC Capital Markets said in a note Friday.Q2 revenue was $449 million, with organic growth of about 14%, while adjusted earnings before interest, taxes, depreciation, and amortization margin reached 19.2%, driven largely by the company's core maintenance, repair and overhaul, or MRO, and distribution businesses, with additional benefit from recent acquisitions, the investment firm said.VSE raised its 2026 revenue growth outlook to about 63% and increased its adjusted EBITDA margin guidance to about 18.9%. Further margin expansion is expected over time, potentially above 21%, helped by growth in the parts business and acquisition mix, according to the note.RBC Capital Markets maintained an outperform rating on VSE and raised the price target to $265 from $240.Shares of VSE were down over 3% in Friday trading.Price: $217.70, Change: $-7.75, Percent Change: -3.44%

$VSEC

Wire1h ago

Illinois Tool Works Raises Quarterly Dividend, Approves $6 Billion Share Buyback Authorization

Illinois Tool Works (ITW) said Friday it raised its quarterly dividend to $1.72 per share from $1.61, payable Oct. 9 to stockholders of record Sept. 30.The company said its board also approved a new authorization to repurchase up to $6 billion of its common stock under a capital allocation strategy, according to a statement.Price: $296.98, Change: $+2.28, Percent Change: +0.77%

$ITW

Wire1h ago

Market Chatter: Rockstar Energy Founder Discloses Big Celsius Stake, Calls for C-Suite Changes

Rockstar Energy founder Russ Savage now holds over 12 million shares of Celsius (CELH), or about 4.7% of the company, and he said the company's chief executive and chief operating officer "need to be fired," CNBC reported Friday, citing an interview with Savage.Savage, who also said the company's brand manager and marketing manager should be let go, volunteered for the CEO position, according to the report."Members of our Board and management team have engaged with Russ Savage many times over the past several years," a Celsius spokesperson toldvia email. "Yesterday, Celsius Holdings reported record second quarter financial results, reflecting continued demand and resilience across our consumer base. We remain focused on executing our total energy portfolio strategy to drive durable, long-term growth," the spokesperson added.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $26.56, Change: $+2.79, Percent Change: +11.72%

$CELH

Wire1h ago

Regenxbio Seen on Track for Duchenne Approval as Data Strengthens, RBC Says

Regenxbio's (RGNX) Duchenne muscular dystrophy gene therapy appears approvable, with efficacy comparable to Sarepta Therapeutics (SRPT) and a more favorable safety profile, as the company moves toward submitting its rolling biologics license application, RBC Capital Markets said Thursday in a report.Regenxbio is on track to file the first module of the BLA this quarter and expects to complete the submission in Q1 2027, RBC said. By that time, the company anticipates having functional data from roughly half of the 30 patients in its fully enrolled pivotal trial, the report said.RBC said the confirmatory study is also fully enrolled and designed to compare two-year functional outcomes against established benchmarks for disease progression, while a larger placebo-controlled trial recommended by European regulators is planned for 2027 to support global filings.RBC reiterated its outperform rating on Regenxbio stock and $19 price target.Price: $10.47, Change: $-0.81, Percent Change: -7.18%

$RGNX

Showing 1-20 of 10620